Advertisement

Journal of Neurology

, Volume 255, Issue 12, pp 1872–1880 | Cite as

Weight loss in neurodegenerative disorders

  • N. A. Aziz
  • M. A. van der Marck
  • H. Pijl
  • M. G. M. Olde Rikkert
  • B. R. Bloem
  • R. A. C. Roos
ORIGINAL COMMUNICATION

Abstract

Unintended weight loss frequently complicates the course of many neurodegenerative disorders and can contribute substantially to both morbidity and mortality. This will be illustrated here by reviewing the characteristics of unintended weight loss in the three major neurodegenerative disorders: Alzheimer’s disease, Parkinson’s disease and Huntington’s disease. A common denominator of weight loss in these neurodegenerative disorders is its typically complex pathophysiology. Timely recognition of the underlying pathophysiological process is of crucial importance, since a tailored treatment of weight loss can considerably improve the quality of life. This treatment is, primarily, comprised of a number of methods of increasing energy intake. Moreover, there are indications for defects in the systemic energy homeostasis and gastrointestinal function, which may also serve as therapeutic targets. However, the clinical merits of such interventions have yet to be demonstrated.

Key words

weight loss neurodegenerative disorders Alzheimer’s disease Parkinson’s disease Huntington’s disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Evans DA, Smith LA, Scherr PA, Albert MS, Funkenstein HH, Hebert LE (1991) Risk of death from Alzheimer’s disease in a community population of older persons. Am J Epidemiol 134(4):403–412PubMedGoogle Scholar
  2. 2.
    Guyonnet S, Nourhashemi F, Ousset PJ, Micas M, Ghisolfi A, Vellas B, et al. (1998) Factors associated with weight loss in Alzheimer’s disease. J Nutr Health Aging 2(2):107–109PubMedGoogle Scholar
  3. 3.
    Craft S (2005) Insulin resistance syndrome and Alzheimer’s disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 26(Suppl 1):65–69PubMedCrossRefGoogle Scholar
  4. 4.
    Craft S, Watson GS (2004) Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3(3):169–178PubMedCrossRefGoogle Scholar
  5. 5.
    Gillette GS, Abellan VK, Alix E, Andrieu S, Belmin J, Berrut G, et al. (2007) IANA (International Academy on Nutrition and Aging) Expert Group: weight loss and Alzheimer’s disease. J Nutr Health Aging 11(1):38–48Google Scholar
  6. 6.
    Tamura BK, Masaki KH, Blanchette P (2007) Weight loss in patients with Alzheimer’s disease. J Nutr Elder 26 (3–4):21–38PubMedCrossRefGoogle Scholar
  7. 7.
    Gillette-Guyonnet S, Nourhashemi F, Andrieu S, de G, I, Ousset PJ, Riviere D, et al. (2000) Weight loss in Alzheimer disease. Am J Clin Nutr 71(2): 637S–642SPubMedGoogle Scholar
  8. 8.
    Buchman AS, Wilson RS, Bienias JL, Shah RC, Evans DA, Bennett DA (2005) Change in body mass index and risk of incident Alzheimer disease. Neurology 65(6):892–897PubMedCrossRefGoogle Scholar
  9. 9.
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34(7):939–944PubMedGoogle Scholar
  10. 10.
    Whitmer RA, Gunderson EP, Barrett- Connor E, Quesenberry CP Jr, Yaffe K (2005) Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330(7504):1360PubMedCrossRefGoogle Scholar
  11. 11.
    Luchsinger JA, Patel B, Tang MX, Schupf N, Mayeux R (2007) Measures of adiposity and dementia risk in elderly persons. Arch Neurol 64(3):392–398PubMedCrossRefGoogle Scholar
  12. 12.
    Nutt JG, Wooten GF (2005) Clinical practice. Diagnosis and initial management of Parkinson’s disease. N Engl J Med 353(10):1021–1027PubMedCrossRefGoogle Scholar
  13. 13.
    Chaudhuri KR, Healy DG, Schapira AH (2006) Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 5(3):235–245PubMedCrossRefGoogle Scholar
  14. 14.
    Bachmann CG, Trenkwalder C (2006) Body weight in patients with Parkinson’s disease. Mov Disord 21(11):1824–1830PubMedCrossRefGoogle Scholar
  15. 15.
    Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A (2003) Weight loss in Parkinson’s disease. Ann Neurol 53(5):676–679PubMedCrossRefGoogle Scholar
  16. 16.
    Abbott RD, Ross GW, White LR, Nelson JS, Masaki KH, Tanner CM, et al. (2002) Midlife adiposity and the future risk of Parkinson’s disease. Neurology 59(7):1051–1057PubMedGoogle Scholar
  17. 17.
    Bates G, Harper PS, Jones L (2002) Huntington’s Disease. Third edition. Oxford University PressGoogle Scholar
  18. 18.
    Kremer HP, Roos RA (1992) Weight loss in Huntington’s disease. Arch Neurol 49(4):349PubMedGoogle Scholar
  19. 19.
    Morales LM, Estevez J, Suarez H, Villalobos R, Chacin DB, Bonilla E (1989) Nutritional evaluation of Huntington disease patients. Am J Clin Nutr 50(1):145–150PubMedGoogle Scholar
  20. 20.
    Djousse L, Knowlton B, Cupples LA, Marder K, Shoulson I, Myers RH (2002) Weight loss in early stage of Huntington’s disease. Neurology 59(9):1325–1330PubMedGoogle Scholar
  21. 21.
    Trejo A, Boll MC, Alonso ME, Ochoa A, Velasquez L (2005) Use of oral nutritional supplements in patients with Huntington’s disease. Nutrition 21(9):889–894PubMedGoogle Scholar
  22. 22.
    Kremer HP (1992) The lateral hypothalamus in Huntington’s, Alzheimer’s and Parkinson’s disease. Leiden, The Netherlands (Thesis)Google Scholar
  23. 23.
    Farrer LA, Meaney FJ (1985) An anthropometric assessment of Huntington’s disease patients and families. Am J Phys Anthropol 67(3):185–194PubMedCrossRefGoogle Scholar
  24. 24.
    Farrer LA, Yu PL (1985) Anthropometric discrimination among affected, at-risk, and not-at-risk individuals in families with Huntington disease. Am J Med Genet 21(2):307–316PubMedCrossRefGoogle Scholar
  25. 25.
    Trejo A, Tarrats RM, Alonso ME, Boll MC, Ochoa A, Velasquez L (2004) Assessment of the nutrition status of patients with Huntington’s disease. Nutrition 20(2):192–196PubMedCrossRefGoogle Scholar
  26. 26.
    Pratley RE, Salbe AD, Ravussin E, Caviness JN (2000) Higher sedentary energy expenditure in patients with Huntington’s disease. Ann Neurol 47(1):64–70PubMedCrossRefGoogle Scholar
  27. 27.
    Lanska DJ, Lanska MJ, Lavine L, Schoenberg BS (1988) Conditions associated with Huntington’s disease at death. A case-control study. Arch Neurol 45(8):878–880PubMedGoogle Scholar
  28. 28.
    Myers RH, Sax DS, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK, et al. (1991) Factors associated with slow progression in Huntington’s disease. Arch Neurol 48(8):800–804PubMedGoogle Scholar
  29. 29.
    National Collaborating Centre for Acute Care (2006) Nutrition support in adults: Oral nutrition support, enteral tube feeding and parenteral nutrition. Report. LondonGoogle Scholar
  30. 30.
    Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW (2006) Central nervous system control of food intake and body weight. Nature 443(7109):289–295PubMedCrossRefGoogle Scholar
  31. 31.
    Sandoval D, Cota D, Seeley RJ (2008) The integrative role of CNS fuel-sensing mechanisms in energy balance and glucose regulation. Annu Rev Physiol 70:513–535PubMedCrossRefGoogle Scholar
  32. 32.
    White HK (2005) Nutrition in advanced Alzheimer’s disease. N C Med J 66(4):307–312PubMedGoogle Scholar
  33. 33.
    Van Raamsdonk JM, Gibson WT, Pearson J, Murphy Z, Lu G, Leavitt BR, et al. (2006) Body weight is modulated by levels of full-length Huntingtin. Hum Mol Genet 15(9):1513–1523PubMedCrossRefGoogle Scholar
  34. 34.
    Hickson M (2006) Malnutrition and ageing. Postgrad Med J 82(963):2–8PubMedCrossRefGoogle Scholar
  35. 35.
    Thomas DR, Ashmen W, Morley JE, Evans WJ (2000) Nutritional management in long-term care: development of a clinical guideline. Council for Nutritional Strategies in Long-Term Care. J Gerontol A Biol Sci Med Sci 55(12):M725–M734PubMedGoogle Scholar
  36. 36.
    Malnutrition Universal Screening Tool. http://www.bapen.org.uk/must_tool. htmlGoogle Scholar
  37. 37.
    Mini Nutritional Assessment. http:// www.nestle-nutrition.com/tools/mna. aspxGoogle Scholar
  38. 38.
    Stratton RJ, King CL, Stroud MA, Jackson AA, Elia M (2006) ‘Malnutrition Universal Screening Tool’ predicts mortality and length of hospital stay in acutely ill elderly. Br J Nutr 95(2):325–330PubMedCrossRefGoogle Scholar
  39. 39.
    Guigoz Y (2006) The Mini Nutritional Assessment (MNA) review of the literature – What does it tell us? J Nutr Health Aging 10(6):466–485PubMedGoogle Scholar
  40. 40.
    Volkert D, Berner YN, Berry E, Cederholm T, Coti BP, Milne A, et al. (2006) ESPEN Guidelines on Enteral Nutrition: Geriatrics. Clin Nutr 25(2): 330–360PubMedCrossRefGoogle Scholar
  41. 41.
    Finley B (1997) Nutritional needs of the person with Alzheimer’s disease: practical approaches to quality care. J Am Diet Assoc 97(10 Suppl 2):S177–S180PubMedCrossRefGoogle Scholar
  42. 42.
    Ragneskog H, Brane G, Karlsson I, Kihlgren M (1996) Influence of dinner music on food intake and symptoms common in dementia. Scand J Caring Sci 10(1):11–17PubMedGoogle Scholar
  43. 43.
    Nijs KA, de Graaf C, Kok FJ, van Staveren WA (2006) Effect of family style mealtimes on quality of life, physical performance, and body weight of nursing home residents: cluster randomised controlled trial. BMJ 332(7551):1180–1184PubMedCrossRefGoogle Scholar
  44. 44.
    Poehlman ET, Dvorak RV (2000) Energy expenditure, energy intake, and weight loss in Alzheimer disease. Am J Clin Nutr 71(2):650S–655SPubMedGoogle Scholar
  45. 45.
    Kishi T, Elmquist JK (2005) Body weight is regulated by the brain: a link between feeding and emotion. Mol Psychiatry 10(2):132–146PubMedCrossRefGoogle Scholar
  46. 46.
    Rigler SK, Webb MJ, Redford L, Brown EF, Zhou J, Wallace D (2001) Weight outcomes among antidepressant users in nursing facilities. J Am Geriatr Soc 49(1):49–55PubMedCrossRefGoogle Scholar
  47. 47.
    Masand PS, Gupta S (2002) Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry 14(3):175–182PubMedGoogle Scholar
  48. 48.
    Deberdt WG, Dysken MW, Rappaport SA, Feldman PD, Young CA, Hay DP, et al. (2005) Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry 13(8):722–730PubMedGoogle Scholar
  49. 49.
    Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. (2006) Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 355(15):1525–1538PubMedCrossRefGoogle Scholar
  50. 50.
    White HK, McConnell ES, Bales CW, Kuchibhatla M (2004) A 6-month observational study of the relationship between weight loss and behavioral symptoms in institutionalized Alzheimer’s disease subjects. J Am Med Dir Assoc 5(2):89–97PubMedCrossRefGoogle Scholar
  51. 51.
    Levi S, Cox M, Lugon M, Hodkinson M, Tomkins A (1990) Increased energy expenditure in Parkinson’s disease. BMJ 301(6763):1256–1257PubMedCrossRefGoogle Scholar
  52. 52.
    Markus HS, Cox M, Tomkins AM (1992) Raised resting energy expenditure in Parkinson’s disease and its relationship to muscle rigidity. Clin Sci (Lond) 83(2):199–204PubMedGoogle Scholar
  53. 53.
    Montaurier C, Morio B, Bannier S, Derost P, Arnaud P, Brandolini-Bunlon M, et al. (2007) Mechanisms of body weight gain in patients with Parkinson’s disease after subthalamic stimulation. Brain 130(Pt 7):1808–1818PubMedCrossRefGoogle Scholar
  54. 54.
    Gaba AM, Zhang K, Marder K, Moskowitz CB, Werner P, Boozer CN (2005) Energy balance in early-stage Huntington disease. Am J Clin Nutr 81(6):1335–1341PubMedGoogle Scholar
  55. 55.
    Toth MJ, Fishman PS, Poehlman ET (1997) Free-living daily energy expenditure in patients with Parkinson’s disease. Neurology 48(1):88–91PubMedGoogle Scholar
  56. 56.
    Mochel F, Charles P, Seguin F, Barritault J, Coussieu C, Perin L, et al. (2007) Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS ONE 2(7):e647PubMedCrossRefGoogle Scholar
  57. 57.
    Chouinard J (2000) Dysphagia in Alzheimer disease: a review. J Nutr Health Aging 4(4):214–217PubMedGoogle Scholar
  58. 58.
    Pfeiffer RF (2003) Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol 2(2):107–116PubMedCrossRefGoogle Scholar
  59. 59.
    Kagel MC, Leopold NA (1992) Dysphagia in Huntington’s disease: a 16-year retrospective. Dysphagia 7(2):106–114PubMedCrossRefGoogle Scholar
  60. 60.
    Hawkes C (2006) Olfaction in neurodegenerative disorder. Adv Otorhinolaryngol 63:133–151PubMedGoogle Scholar
  61. 61.
    Mathey MF, Siebelink E, de Graaf C, van Staveren WA (2001) Flavor enhancement of food improves dietary intake and nutritional status of elderly nursing home residents. J Gerontol A Biol Sci Med Sci 56(4):M200–M205PubMedGoogle Scholar
  62. 62.
    Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998) A 24- week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 50(1):136–145PubMedGoogle Scholar
  63. 63.
    Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal Bianco P, et al. (1999) Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 318(7184):633–638PubMedGoogle Scholar
  64. 64.
    Raskind MA, Peskind ER, Wessel T, Yuan W (2000) Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54(12):2261–2268PubMedGoogle Scholar
  65. 65.
    Vardi J, Oberman Z, Rabey I, Streifler M, Ayalon D, Herzberg M (1976) Weight loss in patients treated longterm with levodopa. Metabolic aspects. J Neurol Sci 30(1):33–40PubMedCrossRefGoogle Scholar
  66. 66.
    Beyer PL, Palarino MY, Michalek D, Busenbark K, Koller WC (1995) Weight change and body composition in patients with Parkinson’s disease. J Am Diet Assoc 95(9):979–983PubMedCrossRefGoogle Scholar
  67. 67.
    Palhagen S, Lorefalt B, Carlsson M, Ganowiak W, Toss G, Unosson M, et al. (2005) Does L-dopa treatment contribute to reduction in body weight in elderly patients with Parkinson’s disease? Acta Neurol Scand 111(1):12–20PubMedCrossRefGoogle Scholar
  68. 68.
    Kumru H, Santamaria J, Valldeoriola F, Marti MJ, Tolosa E (2006) Increase in body weight after pramipexole treatment in Parkinson’s disease. Mov Disord 21(11):1972–1974PubMedCrossRefGoogle Scholar
  69. 69.
    Huntington Study Group (2006) Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66(3):366–372Google Scholar
  70. 70.
    Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AH, et al. (2005) High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology 64(9):1655–1656PubMedCrossRefGoogle Scholar
  71. 71.
    Arabia G, Zappia M, Bosco D, Crescibene L, Bagala A, Bastone L, et al. (2002) Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson’s disease. Neurol Sci 23(Suppl 2):S53–S54PubMedCrossRefGoogle Scholar
  72. 72.
    Gil GP, Ramirez Diaz SP, Ribera Casado JM (2003) Dementia and Nutrition. Intervention study in institutionalized patients with Alzheimer disease. J Nutr Health Aging 7(5):304–308Google Scholar
  73. 73.
    Lauque S, Arnaud-Battandier F, Gillette S, Plaze JM, Andrieu S, Cantet C, et al. (2004) Improvement of weight and fat-free mass with oral nutritional supplementation in patients with Alzheimer’s disease at risk of malnutrition: a prospective randomized study. J Am Geriatr Soc 52(10):1702–1707PubMedCrossRefGoogle Scholar
  74. 74.
    Salas-Salvado J, Torres M, Planas M, Altimir S, Pagan C, Gonzalez ME, et al. (2005) Effect of oral administration of a whole formula diet on nutritional and cognitive status in patients with Alzheimer’s disease. Clin Nutr 24(3):390–397PubMedCrossRefGoogle Scholar
  75. 75.
    World Health Organisation (2004) Human energy requirements: Report of a joint FAO/WHO/UNU expert consultation. FAO FOOD AND NUTRITION TECHNICAL REPORT SERIES 1. Report. RomeGoogle Scholar
  76. 76.
    Gaillard C, Alix E, Salle A, Berrut G, Ritz P (2007) Energy requirements in frail elderly people: a review of the literature. Clin Nutr 26(1):16–24PubMedCrossRefGoogle Scholar
  77. 77.
    de Groot CP, van den BT, van Staveren W (1999) Energy intake and micronutrient intake in elderly Europeans: seeking the minimum requirement in the SENECA study. Age Ageing 28(5):469–474PubMedCrossRefGoogle Scholar
  78. 78.
    Aziz NA, Swaab DF, Pijl H, Roos RA (2007) Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington’s disease: clinical consequences and therapeutic implications. Rev Neurosci 18(3–4):223–251PubMedGoogle Scholar
  79. 79.
    Swaab DF (2004) The human hypothalamus: basic and clinical aspects, part II: neuropathology of the human hypothalamus and adjacent structures. Amsterdam, The Netherlands: ElsevierGoogle Scholar
  80. 80.
    Thannickal TC, Lai YY, Siegel JM (2007) Hypocretin (orexin) cell loss in Parkinson’s disease. Brain 130(Pt 6):1586–1595PubMedCrossRefGoogle Scholar
  81. 81.
    Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, Van Duinen SG, et al. (2007) Hypocretin (orexin) loss in Parkinson’s disease. Brain 130(Pt 6):1577–1585PubMedCrossRefGoogle Scholar
  82. 82.
    Kunig G, Leenders KL, Martin-Solch C, Missimer J, Magyar S, Schultz W (2000) Reduced reward processing in the brains of Parkinsonian patients. Neuroreport 11(17):3681–3687PubMedCrossRefGoogle Scholar
  83. 83.
    Grundman M, Corey-Bloom J, Jernigan T, Archibald S, Thal LJ (1996) Low body weight in Alzheimer’s disease is associated with mesial temporal cortex atrophy. Neurology 46(6):1585–1591PubMedGoogle Scholar
  84. 84.
    Aziz A, Fronczek R, Maat-Schieman M, Unmehopa U, Roelandse F, Overeem S, et al. (2008) Hypocretin and melaninconcentrating hormone in patients with Huntington disease. Brain Pathol 18(4):474–483PubMedGoogle Scholar
  85. 85.
    Rypkema G, Adang E, Dicke H, Naber T, de Swart B, Disselhorst L, et al. (2004) Cost-effectiveness of an interdisciplinary intervention in geriatric inpatients to prevent malnutrition. J Nutr Health Aging 8(2):122–127PubMedGoogle Scholar
  86. 86.
    Hamilton JM, Wolfson T, Peavy GM, Jacobson MW, Corey-Bloom J (2004) Rate and correlates of weight change in Huntington’s disease. J Neurol Neurosurg Psychiatry 75(2):209–212PubMedCrossRefGoogle Scholar
  87. 87.
    Gonzalez De Aguilar JL, Rene F, Dupuis L, Loeffler JP (2003) Neuroendocrinology of neurodegenerative diseases. Insights from transgenic mouse models. Neuroendocrinology 78(5):244–252CrossRefGoogle Scholar
  88. 88.
    Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Bjorkqvist M, Petersen A, et al. (2007) Proteomic profiling of plasma in Huntington’s disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res 6(7):2833–2840PubMedCrossRefGoogle Scholar
  89. 89.
    Dobbs RJ, Dobbs SM, Weller C, Bjarnason IT, Oxlade NL, Charlett A, et al. (2005) Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism. Helicobacter 10(4):267–275PubMedCrossRefGoogle Scholar
  90. 90.
    Mahieux F, Couderc R, Fenelon G, Maachi M (2006) Relationships between weight loss and circulating cytokines in patients with Alzheimer’s disease. Psychol Neuropsychiatr Vieil 4(4):281–286PubMedGoogle Scholar
  91. 91.
    Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I, Stypula G, et al. (1997) Twenty-four hour cortisol release profiles in patients with Alzheimer’s and Parkinson’s disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging 18(3):285–289PubMedCrossRefGoogle Scholar
  92. 92.
    Okun MS, DeLong MR, Hanfelt J, Gearing M, Levey A (2004) Plasma testosterone levels in Alzheimer and Parkinson diseases. Neurology 62(3):411–413PubMedGoogle Scholar
  93. 93.
    Markianos M, Panas M, Kalfakis N, Vassilopoulos D (2005) Plasma testosterone in male patients with Huntington’s disease: relations to severity of illness and dementia. Ann Neurol 57(4):520–525PubMedCrossRefGoogle Scholar
  94. 94.
    Fain JN, Del Mar NA, Meade CA, Reiner A, Goldowitz D (2001) Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington’s disease mutation. Hum Mol Genet 10(2):145–152PubMedCrossRefGoogle Scholar
  95. 95.
    Lodi R, Schapira AH, Manners D, Styles P, Wood NW, Taylor DJ, et al. (2000) Abnormal in vivo skeletal muscle energy metabolism in Huntington’s disease and dentatorubropallidoluysian atrophy. Ann Neurol 48(1):72–76PubMedCrossRefGoogle Scholar
  96. 96.
    Saft C, Zange J, Andrich J, Muller K, Lindenberg K, Landwehrmeyer B, et al. (2005) Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington’s disease. Mov Disord 20(6):674–679PubMedCrossRefGoogle Scholar
  97. 97.
    Vanhanen M, Kivipelto M, Koivisto K, Kuusisto J, Mykkanen L, Helkala EL, et al. (2001) APOE-epsilon4 is associated with weight loss in women with AD: a population-based study. Neurology 56(5):655–659PubMedGoogle Scholar

Copyright information

© Steinkopff-Verlag 2009

Authors and Affiliations

  • N. A. Aziz
    • 1
  • M. A. van der Marck
    • 3
  • H. Pijl
    • 2
  • M. G. M. Olde Rikkert
    • 4
  • B. R. Bloem
    • 3
  • R. A. C. Roos
    • 1
  1. 1.Leiden University Medical CentreDept. of Neurology, K-05-Q 110LeidenThe Netherlands
  2. 2.Dept. of Endocrinology and Metabolic, DiseasesLeiden University Medical CentreLeidenThe Netherlands
  3. 3.Dept. of NeurologyRadboud University Nijmegen Medical CentreNijmegenThe Netherlands
  4. 4.Dept. of Geriatric MedicineRadboud University Nijmegen Medical CentreNijmegenThe Netherlands

Personalised recommendations